Company Overview and News

 
Is Celgene's Stock A Buy The Dip Opportunity?

3h seekingalpha
Celgene's stock is in a downtrend but selling volume picked up on May 21 for no apparent reason.

 
Celgene Corporation: How to Effectively Buy Into CELG Stock

13h investorplace
After years of growth, Celgene Corporation (NASDAQ:CELG) has spent the past eight months suffering from ever-weakening price action. But ‘all good things must eventually come to an end.’ And for those still bullish on CELG a modified fence strategy is the smarter way to position and profit from an overdue change in CELG stock. Let me explain.

 
Who are the Top 3 Biotech Takeover Targets?

13h biospace
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right. The biggest deals have been Sanofi’s acquisition of Bioverativ for about $11.6 billion and Ablynx for $4.8 billion, both in January. Also in January, Celgene Corporation bought Juno Therapeutics for about $9 billion, then shortly afterwards Celgene bought Impact Biomedicines for $1.

3
Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas

18h seekingalpha
My ¨Week in Review¨ blog post appears to have the makings of a permanent feature due to positive feedback received thus far.

 
Celgene, Campbell’s Soup Drop into Monday’s 52-Week Low Club

2018-05-21 247wallst
May 21, 2018: Here are four stocks trading with heavy volume among 66 equities making new 52-week lows in Monday’s session. On the NYSE advancers led decliners by about 2.31 to 1 and on the Nasdaq, advancers led decliners by about 1.51 to 1.

3
5 Top Stock Trades for Tuesday Morning | InvestorPlace

2018-05-21 investorplace
U.S. stocks jumped higher Monday on news that trade tensions between China and the U.S. are cooling off. Can stocks continue higher this week? Here are our top stock trades for Tuesday.

 
Should The FDA Be Shaming Drug Companies? Financial Advisors' Daily Digest

2018-05-21 seekingalpha
The FDA calls out Celgene, Actelion, Novartis, Gilead and other branded drug makers for anti-competitive behavior.

 
Celgene: Still (Looks) Appealing

2018-05-21 seekingalpha
The same setbacks make that investors question recent expensive deals as well, including the rapid increase in net debt.

 
Jounce Therapeutics Tumbles On ASCO Reveal, Is There Salvageable Data?

2018-05-21 seekingalpha
Jounce Therapeutics tumbles on preliminary ASCO results for JTX-2011 but holds an opportunity to recover with newly updated data at the conference.

 
OncoMed Pharmaceuticals: Assessing The Prospect Of A Potential Robust Winner

2018-05-21 seekingalpha
As a promising grower, OncoMed is leveraging on the “more shots on goal” strategy. Despite earlier missed clinical outcomes, the company is brewing stellar molecules that are approaching their binaries.

 
Will 'Public Shaming' Sink Celgene?

2018-05-21 seekingalpha
The FDA posted a list of companies who have been targets of complaints by generic drug makers. CELG topped the list.

 
Venture Capital Deals Of The Week: Amazon And Blue Apron Competitor Gets $50M

2018-05-19 seekingalpha
Welcome to Seeking Alpha’s Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings.

5
CELG / Celgene Corp. 8-K (Current Report)

2018-05-18 sec.gov
UNITED STATES

2
CELG / Celgene Corp. DEFA14A

2018-05-18 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSI

1
Campbell Soup, Celgene Stumble into Friday’s 52-Week Low Club

2018-05-18 247wallst
May 18, 2018: Here are four stocks trading with heavy volume among 70 equities making new 52-week lows in Friday’s session. On the NYSE advancers led decliners by about 1.12 to 1 and on the Nasdaq, decliners led advancers by about 1.03 to 1.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 151020104